Biotech

Vaccine
#Biotech #Cancer vaccines #Infinitopes

Infinitopes secures funding to develop cancer vaccine 

Biotechnology company Infinitopes has raised $35.1 million in a seed financing round to accelerate the development of a precision cancer vaccine.  The latest finance round was co-led by Octopus Ventures and new investor Amplify Bio, with further participation from new investor Macmillan Cancer Support and existing investors Cancer Research Horizons and Manta… Read More

#Business & Investment #News

Node structures in the central nervous system
#Alzheimer's #Biotech #CNS #Insilico Medicine #Parkinson's

Insilico and Hygtia Therapeutics partner on CNS disease drug 

Biotechnology companies Insilico Medicine and Hygtia Therapeutics have announced a co-development collaboration agreement for Insilico’s ISM8969.  The partnership will look to accelerate the global advancement of ISM8969, an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.   The NLRP3 inflammasome is a critical component of the innate immune system but its aberrant activation is recognised… Read More

#Business & Investment #News

#Biology #Biotech #Canada

VoxCell appoints Graham Craig as COO 

Canadian biotechnology company VoxCell has appointed Graham Craig as Chief Commercial Officer (COO).  Craig joins VoxCell from clinical-stage biotechnology company AbCellera with experience in commercialisation and strategic partnerships across the pharmaceutical and biotech sectors. Craig will lead VoxCell’s commercial strategy, including global business development, strategic partnerships, and go-to-market execution as the industry accelerates adoption of… Read More

#News

Eye
#Beacon Therapeutics #Biotech #Ocular diseases

Beacon Therapeutics to advance ocular disease treatment 

Biotechnology company Beacon Therapeutics has raised over $75 million to advance treatments for ocular diseases.  The funding was raised in an oversubscribed Series C financing round, led by Life Sciences at Goldman Sachs Alternatives and with participation from the Retinal Degeneration Fund (RD Fund), the venture arm of Foundation Fighting Blindness. … Read More

#Business & Investment #News

High-throughput screening
#Assays #Biotech #Digital workflow #Drug discovery #Protein #Protein chemistry / Proteomics #Webinar

Webinar: The next evolution of high-throughput protein analysis

In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More

#News

CAR-T cells attacking a cancer cell
#Advanced Therapies #Biotech #CAR T-cell therapy #CARsgen Therapeutics #Dispatch Bio

Biotech collaboration to develop CAR-T therapies 

Biotech companies Dispatch Bio and CARsgen Therapeutics have announced a clinical collaboration to develop innovative CAR-T cell therapies.  The trial will evaluate DISP-11, an investigational therapy leveraging Dispatch’s Flare platform. This includes DV-10, the company’s novel tumour-specific virus, and CARsgen’s zevorcabtagene autoleucel (zevor-cel), an autologous B-cell maturation antigen (BCMA)-targeting CAR-T… Read More

#Business & Investment #News

#Biotech #Financing #Investment

$100m fund set up to invest in biotech companies 

Investment manager Arkin Capital has closed a $100 million financing round to set up Arkin Bio Ventures III, a $100m fund aimed at investing in biotech companies.  Arkin Bio Ventures III will back 10 to 12 pre-clinical to early clinical-stage biotech companies, developing transformative therapies in areas of high unmet… Read More

#Business & Investment #News

#Biotech #bit bio #Drug discovery #Human disease models

Bit.bio to develop human cell models for drug discovery 

Biotech company bit.bio has closed a $50 million Series C funding round to scale human cell models for drug discovery.  The company aims to use the funding to accelerate the development of, and access to, its products, scale its operations globally, expand into the multi-billion toxicology market, bolster its manufacturing operations and generate industry-leading… Read More

#Business & Investment #News

#Biotech #Financing #Metabolic diseases #Obesity

Alveus raises $160m to progress weight loss candidate  

Biotechnology company Alveus Therapeutics has raised $159.8 million to advance its next-generation therapies for obesity and metabolic diseases.  Proceeds from the Series A financing will support Phase II clinical development of ALV-100, the company’s lead programme, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly selective Amylin peptide… Read More

#Business & Investment #News

3d structure of the protein molecule
#Assays #Biotech #Digital workflow #Drug discovery #Protein #Protein chemistry / Proteomics #Webinar

Webinar: A deep dive into high-throughput protein analysis

In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More

#News

Neuronal inclusions in Huntington’s disease
#Biotech #Huntington's disease #LoQus23 Therapeutics

Groundbreaking Huntington’s disease drug set for development 

Biotechnology company LoQus23 Therapeutics has nominated its drug candidate LQT-23 for development as a treatment for Huntington’s Disease (HD).  LQT-23 is a first-in-class oral drug candidate which has shown potential to slow or stop the progression of HD. The candidate works as an allosteric small molecule inhibitor… Read More

#News

Amgen HQ
#Amgen #Biotech #Novel therapeutics #Surfaceome

DISCO partners with Amgen to advance novel cancer therapies 

Biopharmaceuticals company DISCO Pharmaceuticals has entered an exclusive license agreement with biotech company Amgen to advance novel cancer targeted therapies.  The companies aim to develop the therapies for a target mapped on the surface of a cancer cell by DISCO’s proprietary platform.  Under the terms of the agreement, DISCO will… Read More

#Business & Investment #Cancer Research #News

Lab equipment
#Assays #Biotech #Digital workflow #Drug discovery #Protein #Protein chemistry / Proteomics #Webinar

Webinar: Achieve high-throughput, multiplexed protein analysis

In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More

#News

amino acids chain
#Assays #Biotech #Digital workflow #Protein #Webinar

Webinar: How to advance protein analysis

In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More

#News

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #DDW Highlights podcast #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

DDW Highlights: 16 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative treatments showed potential to treat neurodegenerative diseases, allergies and arthritis. Elsewhere,… Read More

#Podcasts

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.  The top stories:   … Read More

#News